Short answer
Inhibrx Biosciences, Inc. (INBX) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$37M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$37M
- −27.9% YoY · −9.6% QoQ
- EPS (diluted)
- −$2.34
- −26.5% YoY · −8.8% QoQ
Source: XBRL data from the Inhibrx Biosciences, Inc. (INBX) Q2 2026 10-Q on SEC EDGAR. USD.
Inhibrx Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- FDA BLA review risk: Form 483 observations issued during ozekibart inspections, potentially delaying review or triggering a complete response letter
- Regulatory safety risk: Prior grade 5 hepatotoxicity caused a partial clinical hold in the ChonDRAgon trial
- Commercialization risk: No marketed products and limited experience building U.S. launch infrastructure for ozekibart
- Development risk: Ozekibart and INBRX-106 remain in active clinical trials with uncertain safety and efficacy outcomes
- Financial risk: Clinical delays could exhaust resources needed to continue development or fund new collaborations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibrx Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.